@ To the Top, I believe they are setting up every for a legitimate run at FDA approval and an excellent future with success.
I have a MBA & a DBA, everything they are doing is just good business. The adding of the 300 million shares before they released the PR, also good business for a company trying to fund clinical trials.
This recent price drop is a result of them financing their clinical trials with dilution, in my opinion. It's kind of acting like a split right now with the price going to about half (except not all at once) of it's previous average value. Like most splits, once the new shares are paid for, it will return to it's prior value.
Remember all, this is a business, and I almost guarantee they don't read this board. The moves they are making are in the best interest of the future of their company, and not necessarily at the whim of it's investors.
